Integrating molecular imaging and genomics for personalized thyroid cancer management

Molecular imaging (radioiodine, FDG-PET, SPECT/CT, PET/MRI) combined with genomic profiling (BRAF, RAS, RET, TERT, TP53, etc.) enhances diagnosis, risk stratification, and selection of targeted therapies in thyroid cancer, advancing precision oncology.

• Hybrid imaging modalities (SPECT/CT, PET/CT, PET/MRI) and novel radiotracers like FDG and NaF improve diagnostic accuracy, especially in aggressive or radioiodine-refractory tumors.
• Genomic profiling identifies actionable alterations (BRAF, RAS, RET, NTRK, TERT, TP53) that guide targeted inhibitor therapy and refine prognosis.
• Bioinformatics and multi-omics analyses (GO, KEGG, Reactome) reveal key pathways dysregulated in thyroid cancer, and machine learning is poised to integrate imaging and genomic data.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.